References analysis of the Wikipedia article "Lysergsäureamide" in the German version

bnf.fr

gallica.bnf.fr

Charles Tanret: Sur la présence d’un nouvel alcaloïde, l’ergotinine, dans le seigle ergoté. In: Comptes rendus hebdomadaires des séances de l’Académie des sciences, 1875, Band 81, S. 896–897. Online archiviert auf Gallica.

Charles Tanret: De l’ergotinine. In: Annales de chimie et de physique, 1879, Band 17, S. 493–512. Online archiviert auf Gallica.

doi.org

Christopher L. Schardl, Daniel G. Panaccione, Paul Tudzynski: Ergot Alkaloids – Biology and Molecular Biology. In: The Alkaloids: Chemistry and Biology – Volume 63. Elsevier 2006, doi:10.1016/S1099-4831(06)63002-2, S. 67.

S. Pakhomova, J. Ondráček, M. Hušak, B. Kratochvíl: Conformation of ergopeptam and ergopeptine alkaloids (ergocristam and ergocristine). In: Zeitschrift für Kristallographie, 1997, Band 212, Nr. 8, S. 593–600, doi:10.1524/zkri.1997.212.8.593.

Adam L. Halberstadt, Landon M. Klein, Muhammad Chatha, Laura B. Valenzuela, Alexander Stratford, Jason Wallach, David E. Nichols, Simon D. Brandt: Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). In: Psychopharmacology, 2019, Band 236, S. 799–808, doi:10.1007/s00213-018-5055-9.

Harold A. Abramson: Lysergic Acid Diethylamide (LSD-25): XXXI. Comparison by Questionnaire of Psychotomimetic Activity of Congeners on Normal Subjects and Drug Addicts. In: British Journal of Psychiatry, 1960, Band 106, S. 1120–1123, doi:10.1192/bjp.106.444.1120.

Laurence Lestel: Itinéraires de chimistes. EDP Sciences, 2007, doi:10.1051/978-2-7598-0315-6.c085, S. 502.

George Barger, Francis Howard Carr: XXXVII.—The alkaloids of ergot. In: Journal of the Chemical Society, Transactions, 1907, Band 91, S. 337–353, doi:10.1039/CT9079100337.

F. Kraft: Ueber das Mutterkorn. In: Archiv der Pharmazie, 1906, Band 244, Nr. 4–5, S. 336–359, doi:10.1002/ardp.19062440411.

Arthur Stoll, Albert Hofmann: Die Alkaloide der Ergotoxingruppe: Ergocristin, Ergokryptin und Ergocornin. 7. Mitteilung über Mutterkornalkaloide. In: Helvetica Chimica Acta, 1943, Band 26, Nr. 5, S. 1570–1601, doi:10.1002/hlca.19430260522.

Michael Radcliffe Lee: The history of ergot of rye (Claviceps purpurea) II: 1900–1940. In: Journal of the Royal College of Physicians of Edinburgh, 2009, Band 39, Nr. 4, S. 365–369, doi:10.4997/JRCPE.2009.416.

Arthur Stoll, Albert Hofmann: Partialsynthese von Alkaloiden vom Typus des Ergobasins. 6. Mitteilung über Mutterkornalkaloide. In: Helvetica Chimica Acta, 1943, Band 26, Nr. 3, S. 944–965, doi:10.1002/hlca.19430260326.

Michael Radcliffe Lee: The history of ergot of rye (Claviceps purpurea) III: 1940–80. In: Journal of the Royal College of Physicians of Edinburgh, 2010, Band 40, Nr. 1, S. 77–80, doi:10.4997/jrcpe.2010.115.

Albert Sjoerdsma, Michael G. Palfreyman: History of serotonin and serotonin disorders. In: Annals of the New York Academy of Sciences, 1990, Band 600, S. 1–8, doi:10.1111/j.1749-6632.1990.tb16869.x.

J. H. Gaddum, C. O. Hebb, Ann Silver, A. A. B. Swan: 5-Hydroxytryptamine. Pharmacological action and destruction in perfused lungs. In: Quarterly Journal of Experimental Physiology and Cognate Medical Sciences, 1953, Band 38, Nr. 4, S. 255–262, doi:10.1113/expphysiol.1953.sp001037.

D. W. Woolley, E. Shaw: A biochemical and pharmacological suggestion about certain mental disorders. In: Proceedings of the National Academy of Sciences of the United States of America, 1954, Band 40, Nr. 4, S. 228–231, doi:10.1073/pnas.40.4.228.

E. Shaw, D. W. Woolley: Some Serotoninlike Activities of Lysergic Acid Diethylamide. In: Science, 1956, Band 124, Nr. 3212, S. 121–122, doi:10.1126/science.124.3212.121.

A. Cerletti, E. Rothlin: Role of 5-Hydroxytryptamine in Mental Diseases and its Antagonism to Lysergic Acid Derivatives. In: Nature, 1955, Band 176, Nr. 4486, S. 785–786, doi:10.1038/176785a0.

David E. Nichols: Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD). In: ACS Chemical Neuroscience, 2018, Band 9, Nr. 10, S. 2331–2343, doi:10.1021/acschemneuro.8b00043.

Nadine Weidman: Matthew Oram. The Trials of Psychedelic Therapy: LSD Psychotherapy in America (Buchbesprechung). In: Isis, 2020, Band 111, Nr. 1, doi:10.1086/707842. Online auf der Website der University of Chicago (PDF) abgerufen am 1. August 2021.

Matthew Oram: Prohibited or regulated? LSD psychotherapy and the United States Food and Drug Administration. In: History of Psychiatry, 2016, Band 27, Nr. 3, S. 290–306, doi:10.1177/0957154X16648822.

Daniel Wacker, Sheng Wang, John D. McCorvy, Robin M. Betz, A. J. Venkatakrishnan, Anat Levit, Katherine Lansu, Zachary L. Schools, Tao Che, David E. Nichols, Brian k. Shoichet, Ron O. Dror, Bryan L. Roth: Crystal Structure of an LSD-Bound Human Serotonin Receptor. In: Cell, 2017, Band 168, S. 377–389, doi:10.1016/j.cell.2016.12.033.

P. J. Koehler, P. C. Tfelt-Hansen: History of Methysergide in Migraine. In: Cephalalgia, 2008, Band 28, Nr. 11, S. 1126–1135, doi:10.1111/j.1468-2982.2008.01648.x

Matthias Karst, John H. Halpern, Michael Bernateck, Torsten Passie: The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series. In: Cephalalgia, 2010, Band 30, Nr. 9, S. 1140–1144, doi:10.1177/0333102410363490.

Wesley K. Kroeze, Maria F. Sassano, Xi-Ping Huang, Katherine Lansu, John D. McCorvy, Patrick M. Giguère, Noah Sciaky, Bryan L. Roth: PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. In: Nature Structural & Molecular Biology, 2015, Band 22, S. 362–369, doi:10.1038/nsmb.3014.

Matthias E. Liechti: Modern Clinical Research on LSD. In: Neuropsychopharmacology, 2017, Band 42, S. 2114–2127, doi:10.1038/npp.2017.86.

Vargas MV, Dunlap LE, Dong C et al.: Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. In: Science. 379. Jahrgang, Nr. 6633, 2023, S. 700–706, doi:10.1126/science.adf0435, PMID 36795823.

David E. Nichols, Eric L. Barker: Psychedelics. In: Pharmacological Reviews, 2016, Band 68, Nr. 2, S. 264–355, doi:10.1124/pr.115.011478.

Wallach J, Cao AB, Calkins MM, et al.: Identification of 5-HT 2A Receptor Signaling Pathways Responsible for Psychedelic Potential. In: bioRxiv. Vorschauversion. Jahrgang, 2023, doi:10.1101/2023.07.29.551106, PMID 37577474, PMC 10418054 (freier Volltext).

Ramona M. Rodriguiz, Vineet Nadkarni, Christopher R. Means, Vladimir M. Pogorelov, Yi-Ting Chiu, Bryan L. Roth, William C. Wetsel: LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1. In: Scientific Reports, 2021, Band 11, 17690, doi:10.1038/s41598-021-96736-3.

Lewis V, Bonniwell EM, Lanham JK et al.: A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. In: Cell Rep. 42. Jahrgang, Nr. 3, 2023, S. 112203, doi:10.1016/j.celrep.2023.112203, PMID 36884348, PMC 10112881 (freier Volltext).

Olson DE: Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity. In: Biochemistry. 61. Jahrgang, Nr. 3, 2022, S. 127–136, doi:10.1021/acs.biochem.1c00812, PMID 35060714, PMC 9004607 (freier Volltext).

Moliner R, Girych M, Brunello CA et al.: Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. In: Nat Neurosci. 26. Jahrgang, Nr. 6, 2023, S. 1032–1041, doi:10.1038/s41593-023-01316-5, PMID 37280397, PMC 10244169 (freier Volltext).

Casarotto PC, Girych M, Fred SM et al.: Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. In: Cell. 184. Jahrgang, Nr. 5, 2021, S. 1299–1313.e19, doi:10.1016/j.cell.2021.01.034, PMID 33606976, PMC 7938888 (freier Volltext).

Daniel Wacker, Chong Wang, Vsevolod Katritch, Gye Won Han, Xi-Ping Huang, Eyal Vardy, John D. McCorvy, Yi Jiang, Meihua Chu, Fai Yiu Siu, Wei Liu, H. Eric Xu, Vadim Cherezov, Bryan L. Roth, Raymond C. Stevens: Structural Features for Functional Selectivity at Serotonin Receptors. In: Science, 2013, Band 340, Nr. 6132, S. 615–619, doi:10.1126/science.1232808.

John D. McCorvy, Daniel Wacker, Sheng Wang, Bemnat Agegnehu, Jing Liu, Katherine Lansu, Alexandra R. Tribo, Reid H. J. Olsen, Tao Che, Jian Jin, Bryan L. Roth: Structural determinants of 5-HT_2B receptor activation and biased agonism. In: Nature Structural & Molecular Biology, 2018, Band 25, S. 787–796, doi:10.1038/s41594-018-0116-7.

Norio Ogawa, Ken-ichi Tanaka, Masato Asanuma: Bromocriptine Markedly Suppresses Levodopa-Induced Abnormal Increase of Dopamine Turnover in the Parkinsonian Striatum. In: Neurochemical Research, 2000, Band 25, Nr. 6, S. 755–758, doi:10.1023/A:1007530720544.

Danuta Marona-Lewicka, David E. Nichols: Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. In: Pharmacology Biochemistry and Behavior, 2007, Band 87, Nr. 4, S. 453–461, doi:10.1016/j.pbb.2007.06.001.

Peer C. Tfelt-Hansen: Triptans and ergot alkaloids in the acute treatment of migraine: similarities and differences. In: Expert Review of Neurotherapeutics, 2013, Band 13, Nr. 9, S. 961–963, doi:10.1586/14737175.2013.832851.

Val. J. Watts, Cindy P. Lawler, David R. Fox, Kim A. Neve, David E. Nichols, Richard B. Mailman: LSD and structural analogs: pharmacological evaluation at D₁ dopamine receptors. In: Psychopharmacology, 1995, Band 118, S. 401–409, doi:10.1007/BF02245940.

Adam L. Halberstadt, Muhammad Chatha, Adam K. Klein, John D. McCorvy, Markus R. Meyer, Lea Wagmann, Alexander Stratford, Simon D. Brandt: Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD). In: Neuropharmacology, 2020, Band 172, S. 107856, doi:10.1016/j.neuropharm.2019.107856.

Leigh D. Coney, Larissa J. Maier, Jason A. Ferris, Adam R. Winstock, Monica J. Barratt: Genie in a blotter: A comparative study of LSD and LSD analogues’ effects and user profile. In: Human Psychopharmacology: Clinical and Experimental, 2017, Band 32, Nr. 3, e2599, doi:10.1002/hup.2599.

Jie Yin, Kuang-Yui M. Chen, Mary J. Clark, Mahdi Hijazi, Punita Kumari, Xiao-Chen Bai, Roger K. Sunahara, Patrick Barth, Daniel M. Rosenbaum: Structure of a D2 dopamine receptor-G-protein complex in a lipid membrane. In: Nature, 2020, Band 584, Nr. 7819, S. 125–129, doi:10.1038/s41586-020-2379-5.

Youwen Zhuang, Peiyu Xu, Chunyou Mao, Lei Wang, Brian Krumm, X. Edward Zhou, Sijie Huang, Heng Liu, Xi Cheng, Xi-Ping Huang, Dan-Dan Shen, Tinghai Xu, Yong-Feng Liu, Yue Wang, Jia Guo, Yi Jiang, Hualiang Jiang, Karsten Melcher, Bryan L. Roth, Yan Zhang, Cheng Zhang, H. Eric Xu: Structural insights into the human D1 and D2 dopamine receptor signaling complexes. In: Cell, 2021, Band 184, Nr. 4, S. 931–942.e18, doi:10.1016/j.cell.2021.01.027.

David E. Nichols, Stewart Frescas, Danuta Marona-Lewicka, Deborah M. Kurrasch-Orbaugh: Lysergamides of Isomeric 2,4-Dimethylazetidines Map the Binding Orientation of the Diethylamide Moiety in the Potent Hallucinogenic Agent N,N-Diethyllysergamide (LSD). In: Journal of Medicinal Chemistry, 2002, Band 45, Nr. 19, S. 4344–4349, doi:10.1021/jm020153s.

David E. Nichols, A. Monte, X. Huang, D. Marona-Lewick: Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. In: Behavioural Brain Research. 1995, Band 73, Nr. 1–2, S. 117–119, doi:10.1016/0166-4328(96)00080-0

Xuemei Huang, Danuta Marona-Lewicka, Robert C. Pfaff, David E. Nichols: Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. In: Pharmacology Biochemistry and Behavior, 1994, Band 47, Nr. 3, S. 667–673, doi:10.1016/0091-3057(94)90172-4.

Kuglae Kim, Tao Che, Ouliana Panova, Jeffrey F. DiBerto, Jiankun Lyu, Brian E. Krumm, Daniel Wacker, Michael J. Robertson, Alpay B. Seven, David E. Nichols, Brian K. Shoichet, Georgios Skiniotis, Bryan L. Roth: Structure of a Hallucinogen-Activated Gq-Coupled 5-HT_2A Serotonin Receptor. In: Cell, 2020, Band 182, Nr. 6, S. 1574–1588.e19, doi:10.1016/j.cell.2020.08.024.

Andrew J. Hoffman, David E. Nichols: Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. In: Journal of Medicinal Chemistry, 1985, Band 28, Nr. 9, S. 1252–1255, doi:10.1021/jm00147a022.

Lea Wagmann, Lilian H. J. Richter, Tobias Kehl, Franziska Wack, Madeleine Pettersson Bergstrand, Simon D. Brandt, Alexander Stratford, Hans H. Maurer, Markus R. Meyer: In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. In: Analytical and Bioanalytical Chemistry, 2019, Band 411, S. 4751–4763, doi:10.1007/s00216-018-1558-9.

Patrick Vizeli, Isabelle Straumann, Friederike Holze, Yasmin Schmid, Patrick C. Dolder, Matthias E. Liechti: Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. In: Scientific Reports, 2021, Band 11, Nr. 1, 10851 doi:10.1038/s41598-021-90343-y.

U. Bredberg, G. S. Eyjolfsdottir, L. Paalzow, P. Tfelt-Hansen, V. Tfelt-Hansen: Pharmacokinetics of Methysergide and its Metabolite Methylergometrine in Man. In: European Journal of Clinical Pharmacology, 1986, Band 30, S. 75–77, doi:10.1007/BF00614199.

Pieter S. Steyn: Mycotoxins, general view, chemistry and structure. In: Toxicology Letters, 1995, Band 82–83, S. 843–851, doi:10.1016/0378-4274(95)03525-7.

Mervyn J. Eadie: Convulsive ergotism: epidemics of the serotonin syndrome? In: The Lancet Neurology, 2003, Band 2, Nr. 7, S. 429–434, doi:10.1016/S1474-4422(03)00439-3.

Sarah Belser-Ehrlich, Ashley Harper, John Hussey, Robert Hallock: Human and cattle ergotism since 1900: Symptoms, outbreaks, and regulations. In: Toxicology and Industrial Health, 2012, Band 29, Nr. 4, S. 307–316, doi:10.1177/0748233711432570.

S. Srisuma, E. J. Lavonas, W. Wananukul: Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors. In: Clinical Toxicology, 2014, Band 52, Nr. 7, S. 674–677, doi:10.3109/15563650.2014.933230.

G. Roberto, E. Raschi, C. Piccinni, V. Conti, L. Vignatelli, R. D’Alessandro, F. De Ponti, E. Poluzzi: Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies. In: Cephalalgia, 2015, Band 35, Nr. 2, S. 118–131, doi:10.1177/0333102414550416.

Dennis Mulac, Hans-Ulrich Humpf: Cytotoxicity and accumulation of ergot alkaloids in human primary cells. In: Toxicology, 2011, Band 282, Nr. 3, S. 112–121, doi:10.1016/j.tox.2011.01.019.

David E. Nichols, Charles S. Grob: Is LSD toxic? In: Forensic Science International, 2018, Band 284, S. 141–145, doi:10.1016/j.forsciint.2018.01.006.

Dino Luethi, Matthias E. Liechti: Designer drugs: mechanism of action and adverse effects. In: Archives of Toxicology, 2020, Band 94, S. 1085–1133, doi:10.1007/s00204-020-02693-7.

Nina Gerhards, Lisa Neubauer, Paul Tudzynski, Shu-Ming Li: Biosynthetic Pathways of Ergot Alkaloids. In: Toxins, 2014, Band 6, Nr. 12, S. 3281–3295, doi:10.3390/toxins6123281.

Telmo Correia, Nicolas Grammel, Ingo Ortel, Ullrich Keller, Paul Tudzynski: Molecular Cloning and Analysis of the Ergopeptine Assembly System in the Ergot Fungus Claviceps purpurea. In: Chemistry & Biology, 2003, Band 10, Nr. 12, S. 1281–1292, doi:10.1016/j.chembiol.2003.11.013.

E. L. Komarova, O. N. Tolkachev: The Chemistry of Peptide Ergot Alkaloids. Part 1. Classification and Chemistry of Ergot Peptides. In: Pharmaceutical Chemistry Journal, 2001, Band 35, S. 504–513, doi:10.1023/A:1014050926916.

Edmund C. Kornfeld, E. J. Fornefeld, G. Bruce Kline, Marjorie J. Mann, Dwight E. Morrison, Reuben G. Jones, and Robert B. Woodward: The Total Synthesis of Lysergic Acid. In: Journal of the American Chemical Society, 1956, Band 78, Nr. 13, S. 3087–3114, doi:10.1021/ja01594a039.

s. Shinsuke Inuki, Akira Iwata, Shinya Oishi, Nobutaka Fujii, Hiroaki Ohno: Enantioselective Total Synthesis of (+)-Lysergic Acid, (+)-Lysergol, and (+)-Isolysergol by Palladium-Catalyzed Domino Cyclization of Allenes Bearing Amino and Bromoindolyl Groups. In: The Journal of Organic Chemistry, 2011, Band 76, Nr. 7, S. 2072–2083, doi:10.1021/jo102388e, m. w. N.

A. Stoll, A. Hofmann: Die optisch aktiven Hydrazide der Lysergsäure und der Isolysergsäure. (4. Mitteilung über Mutterkornalkaloide). In: Helvetica Chimica Acta, 1943, Band 26, Nr. 3, S. 922–928, doi:10.1002/hlca.19430260324.

Fatima N. Johnson, Istvan E. Ary, David G. Teiger, Ronald J. Kassel: Emetic Activity of Reduced Lysergamides. In: Journal of Medicinal Chemistry, 1973, Band 16, Nr. 5, S. 532–537, doi:10.1021/jm00263a028.

William L. Garbrecht: Synthesis of Amides of Lysergic Acid. In: The Journal of Organic Chemistry, 1959, Band 24, Nr. 3, S. 368–372, doi:10.1021/jo01085a024.

F. Troxler, A. Hofmann: Substitutionen am Ringsystem der Lysergsäure II. Alkylierung. 44. Mitteilung über Mutterkornalkaloide. In: Helvetica Chimica Acta, 1957, Band 40, Nr. 6, S. 1721–1732, doi:10.1002/hlca.19570400620.

F. Troxler, A. Hofmann: Substitutionen am Ringsystem der Lysergsäure I. Substitutionen am Indol-Stickstoff. 43. Mitteilung über Mutterkornalkaloide. In: Helvetica Chimica Acta, 1957, Band 40, Nr. 6, S. 1706–1720, doi:10.1002/hlca.19570400619.

F. Troxler, A. Hofmann: Substitutionen am Ringsystem der Lysergsäure. III. Halogenierung. 45. Mitteilung über Mutterkornalkaloide. In: Helvetica Chimica Acta, 1957, Band 40, Nr. 7, S. 2160–2170, doi:10.1002/hlca.19570400716.

E. L. Komarova, O. N. Tolkachev: The Chemistry of Peptide Ergot Alkaloids. Part 2. Analytical Methods for Determining Ergot Alkaloids. In: Pharmaceutical Chemistry Journal, 2001, Band 35, S. 542–549, doi:10.1023/A:1014706301632.

Colin Crews: Analysis of Ergot Alkaloids. In: Toxins, 2015, Band 7, Nr. 6, S. 2024–2050, doi:10.3390/toxins7062024.

e-periodica.ch

Arthur Stoll: Zur Kenntnis der Mutterkornalkaloide. In: Verhandlungen der Schweizerischen Naturforschenden Gesellschaft, 1920, Band 101, S. 190–191. Online archiviert auf e-periodica.ch (ETH Zürich).

K. Spiro, A. Stoll: Über die wirksamen Substanzen des Mutterkorns. In: Verhandlungen der Schweizerischen Naturforschenden Gesellschaft, 1920, Band 101, S. 235–236. Online archiviert auf e-periodica.ch (ETH Zürich).

europa.eu

eur-lex.europa.eu

Verordnung (EU) 2021/1399 der Kommission vom 24. August 2021 zur Änderung der Verordnung (EG) Nr. 1881/2006 hinsichtlich der Höchstgehalte an Mutterkorn-Sklerotien und Ergotalkaloiden in bestimmten Lebensmitteln. Online auf EUR-Lex, abgerufen am 23. Januar 2022.

Verordnung (EG) Nr. 111/2005 des Rates vom 22. Dezember 2004 zur Festlegung von Vorschriften für die Überwachung des Handels mit Drogenaustauschstoffen zwischen der Gemeinschaft und Drittländern. Online auf EUR-Lex, abgerufen am 31. Juli 2021.

nih.gov

ncbi.nlm.nih.gov

M. Peraica, B. Radić, A. Lucić, M. Pavlović: Toxic effects of mycotoxins in humans. In: Bulletin of the World Health Organization, 1999, Band 77, Nr. 9, S. 754–766, PMID 10534900.

uni-freiburg.de

freidok.uni-freiburg.de

Verena K. Angerer: Neue psychoaktive Substanzen in der forensischen Toxikologie: Synthetische Cannabinoide – Eine unendliche Geschichte? Dissertation, Albert-Ludwigs-Universität Freiburg im Breisgau 2017, S. 15. Online auf der Website der Universität Freiburg, abgerufen am 1. August 2021.

Lysergsäureamide (German Wikipedia)

admin.ch

fedlex.admin.ch

bgbl.de

bka.gv.at

ris.bka.gv.at

bnf.fr

gallica.bnf.fr

bundesrat.de

doi.org

drugpatentwatch.com

e-periodica.ch

europa.eu

eur-lex.europa.eu

eve-rave.net

jstor.org

nih.gov

ncbi.nlm.nih.gov

pschyrembel.de

uchicago.edu

journals.uchicago.edu

uni-freiburg.de

freidok.uni-freiburg.de

who.int